OncoTargets and Therapy (Sep 2019)
Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature
Abstract
Linglong Xu, Xiaoxiao Ding, Limei Ying, Xiaochang Zhang, Nina Lu Department of Hematology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, People’s Republic of ChinaCorrespondence: Linglong XuDepartment of Hematology, Taizhou Central Hospital (Taizhou University Hospital), 999 Donghai Road, Taizhou, Zhejiang 318000, People’s Republic of ChinaTel +86 576 8852 6258Email [email protected]: MYD88 mutation has been reported in various lymphomas, specifically in lymphoplasmacytic lymphoma. Yet, the mutation has not been reported in primary follicular lymphoma. Here, we present a 62-year-old male with follicular lymphoma who had an MYD88 L265P somatic mutation and monoclonal IgM gammopathy. He received four cycles of R-CHOP immunochemotherapy. Interim PET/CT evaluation indicated a state of stable disease (SD). Neither did serum IgM remarkably drop. He was then given a bortezomib-contained regimen which significantly reduced the level of serum IgM. To the best of our knowledge, this is the first report of follicular lymphoma with monoclonal IgM and MYD88 L265P mutation. The present case indicated bortezomib may benefit these patients.Keywords: follicular lymphoma, monoclonal gammopathy, immunochemotherapy, MYD88 mutation
